NCT00114257View on ClinicalTrials.gov

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2006

Conditions
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

decitabine

DRUG

romidepsin

Trial Locations (1)

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00114257 - Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders | Biotech Hunter | Biotech Hunter